We Can Stop Duplicate Financing Fraud This Year, Says International Chamber of Commerce United Kingdom as New Initiative Launched
7.2.2023 15:34:00 EET | Business Wire | Press release
The International Chamber of Commerce United Kingdom (ICC United Kingdom) has announced a new initiative to strengthen the UK finance industry against the impacts of duplicate financing fraud. The Centre for Digital Trade and Innovation (C4DTI)-led initiative will leverage ICC United Kingdom’s convening capabilities to deliver this flagship project under the C4DTI’s Shutting fraudsters out of trade workstream in partnership with MonetaGo.
Duplicate financing is defined as fraud by which fraudsters get the same transaction financed multiple times. Today, a fraudster can go to multiple banks and have the exact same trade financed, without the banks having the ability to cross check. Regulation around confidentiality hinders banks from sharing information on deals they have financed with other banks, creating a grey area that fraudsters leverage to finance the same transaction multiple times. It is a fraud typology impossible to detect via existing siloed AI and KYC tools and requires an innovative and collaborative ecosystem approach. Duplicate financing has therefore syphoned billions of dollars from the financial services community globally.
By the end of 2023, UK banks will be able to ensure that a transaction has not been financed multiple times in the banking community. Although some details remain confidential, the majority of trade banks in the UK have agreed to take part in the project, with more expected to join in due course. This would make the UK the first G7 economy to tackle this issue, saving hundreds of millions of pounds in lost funding that can be better spend facilitating real trade transactions. In the context of a global trade finance gap of $1.7 trillion, it is crucial that penny goes to legitimate businesses.
"Technological innovation will change the game in finance over the next five years, with the UK taking a leading charge in MLETR legislative reforms. This will unlock much-needed innovation which will revolutionise finance," said Chris Southworth, Secretary General of ICC United Kingdom.
"Not all innovations require years to deliver value, and eliminating duplicate financing fraud, in partnership with MonetaGo, is a great example of an existing solution that will have a significant impact in the short term. ICC United Kingdom is uniquely positioned to help accelerate the elimination of duplicate financing fraud, with the aim that every financed Pound makes its way to a business raising finance legitimately by the end of 2023."
To combat duplicate financing fraud, ICC United Kingdom has partnered with financial technology provider MonetaGo. The firm's service has been live since 2018, processing millions of transactions in Asia and actively preventing duplicate financing in receivables discounting and invoice finance. The service is available on SWIFT's new API Gateway service offering, enabling its 11,000+ member financial institutions to access the MonetaGo service. Built from the ground up on international standards, this fraud prevention utility connects to a wide array of financing platforms.
Notes to editors:
ICC United Kingdom is the UK representative office of the International Chamber of Commerce, the largest world business organisation representing 45 million companies in 100 countries. ICC’s mission is to promote inclusive, sustainable and green trade. Its rules underpin $25 trillion of global trade.
ICC United Kingdom represents the voice of British business at the inter-governmental level, including the United Nations, G20 and World Trade. Organization. For further information, please visit iccwbo.uk .
The Centre for Digital Trade and Innovation (C4DTI) is an ICC United Kingdom-led, global initiative based in Teesside in the North-East of England. Launched in April 2022 as a public, private partnership, its mission is to accelerate the digitalisation of UK trade and promote the adoption of interoperable legal, standards and rules frameworks. For further information, please visit c4dti.co.uk .
MonetaGo's Secure Financing solution enables banks and traditional financiers as well as non-bank financial institutions, fintechs and trade finance funds to check for duplication of financing requests linked to invoices, bills of lading, air waybills, warehouse receipts, purchase orders and other trade-related documents.
Since entering full production in 2018, the Secure Financing system has processed over 4 million transactions and has been integrated into SWIFT's API-enabled infrastructure as the first third-party service on SWIFT, providing its member institutions with an important tool to combat duplicate financing fraud in trade and supply chain finance.
MonetaGo has recently been awarded Best Fintech Startup in Trade 2022 by Global Trade Review, while its Secure Financing solution has been recognised as Best Solution in Trade Finance at the AMTD DigFin Innovation Awards at the Hong Kong Fintech Week 2021, and as Most Effective Bank-Fintech Partnership at the IBS Intelligence Global Fintech Innovation Awards 2021. For further information, please visit monetago.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005735/en/
Contact information
Michael Keating; press@iccwbo.uk; +44 7542 935329
Matt Stapleton; matt@monetago.com; +65 9654 9402
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
